Gilead, BMS, Janssen facing HIV generic antitrust suit

Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus (HIV).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

BMS sues AstraZeneca for infringing cancer treatment drug

26 January 2023 US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Big Pharma

Russian drugmakers bypass Gilead to unveil COVID-19 generic

4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

More on this story

Big Pharma

BMS sues AstraZeneca for infringing cancer treatment drug

26 January 2023 US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

Big Pharma

Russian drugmakers bypass Gilead to unveil COVID-19 generic

More on this story

Big Pharma

BMS sues AstraZeneca for infringing cancer treatment drug

26 January 2023 US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

Big Pharma

Russian drugmakers bypass Gilead to unveil COVID-19 generic